Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA. The ‘rolling’ biologics ...
Most data tools force you to choose: fast or real-time. With Deephaven's revolutionary live dataframes, you get both. Process streaming data at millisecond speeds while your AI assistant helps you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback